tiprankstipranks
pc:varmx

VarmX

VarmX is a biotechnology company based in Leiden, the Netherlands, specializing in the development of innovative therapies for patients on direct oral anticoagulants targeting activated Factor Xa and those with inherited coagulation disorders. The company's lead product, VMX-C001, is designed to bypass the anticoagulation effects of Factor Xa inhibitors, rapidly restoring coagulation in patients experiencing severe bleeding or requiring urgent surgery. VarmX's efforts address a significant unmet need in emergency care, with no fully approved therapeutic agents currently available in the E.U. or the U.S. for such conditions.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$117M
Total Amount Raised$117M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$117M
Latest Funding Amount$117M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 16, 2025
Series B
$117.00M

Investors

Investor Name
Funding Round

Related News and Analysis